Biotech Startups

Valence Labs is an AI research engine that develops computational models to predict cellular responses to genetic and chemical interventions for drug discovery. The company focuses on building virtual cells to accelerate the identification of effective therapeutics.

1 investor

VALFIX develops a transcatheter mitral valve repair system with a robotic interface, designed to convert open-heart valve surgery into a minimally invasive transcatheter procedure. The technology targets patients with mitral valve disease and heart failure.

1 investor

Vali provides an AI-assisted platform for karyotyping analysis, where users upload metaphase images and receive cytogenetic results within 24 hours. It serves cytogenetics labs and clinicians, combining artificial intelligence with expert review in the healthtech/diagnostics space.

1 investor

1 investor

Validfor provides computerized system validation (CSV) software and consulting for the life sciences and pharmaceutical industry, covering validation management, data integrity, and quality assurance. It serves regulated companies needing to demonstrate compliance of their computerized systems.

1 investor

Valius is a molecular oncology company that develops tools to understand cancer cell behavior and enable targeted drug development and personalized therapies. It serves clinical and pharmaceutical organizations focused on improving cancer treatment outcomes.

1 investor

ValleyDAO provides funding and community support to research scientists and entrepreneurs developing unconventional biotech projects, offering grants up to $250k with rapid turnaround and access to a network of investors and thought leaders.

1 investor

Valora Therapeutics is a biotech company developing antibody-lectin chimera (AbLec) therapeutics that target cell-surface glycans for immuno-oncology and immunotherapy applications. Its work builds on glycobiology and bioorthogonal chemistry research.

1 investor

Valorize Bioscience uses a patented process to modify the color, taste, aroma, and texture of insect proteins while preserving their nutritional content, addressing sensory limitations that have restricted their use. The company aims to broaden the range of consumable product applications for insect-based proteins.

1 investor

Valorum is a biosimilars company focused on commercializing biosimilar therapies with an emphasis on supply continuity, disciplined pricing, and buy-and-bill partnership models for physician practices, with an initial focus on oncology and ophthalmology. It serves clinicians and specialty care practices in the United States.

1 investor

ValoTx develops oncolytic virus-based immunotherapies that combine viral vector technology with peptide vaccination to treat cancer. The company leverages a patented platform to rapidly create personalized and disease-specific immunotherapies targeting multiple cancer types.

1 investor

Valted Seq builds an end-to-end single cell analysis platform using robotics and AI, and has assembled a large database of single cell brain samples to support biomarker and therapeutic target discovery. It focuses on neurodegenerative diseases such as Alzheimer's and Parkinson's for use in healthcare and life sciences research.

1 investor

Valthos develops AI systems to identify biological threats and design medical countermeasures in real time for biodefense applications.

1 investor

A biomanufacturing company with deep expertise in bioprocessing, process development, and chemically-defined media systems, led by a team of scientists with extensive experience in cell therapy and biologics manufacturing.

1 investor

Vanda is a biopharmaceutical company that develops new medicines, using genetics and genomics to guide drug discovery, clinical trials, and commercial positioning of its compounds. It works to advance novel approaches for delivering these medicines to patients.

1 investor

Vandria is a pharmaceutical development company focused on translating scientific innovation into first-in-class therapeutics. The company's management team specializes in mitochondrial function and neurological disease treatment.

1 investor

1 investor

Drug development company creating small-molecule procaspase-3 activators as targeted oncology therapeutics.

1 investor

Vantage Biosciences develops clinical-stage drug therapies for retinal and other diseases, with a focus on the AOC3 target and its role in liver and eye disease. The company works with a network of preclinical and clinical experts to advance therapeutics where existing treatment options are limited.

1 investor

Vantage Group develops release agents and related formulations used in food production lines to prevent products from sticking to equipment during baking and processing. It serves plant managers and manufacturers of baked and processed foods.

1 investor

1 investor

1 investor

VascuBio Innovation develops microfluidics, biomaterials, and biofabrication platforms—including bioreactors, screening systems, and organ-on-chip technologies—for drug screening, tissue engineering, and regenerative medicine. Founded on academic research connected to McGill University, it serves researchers and industry seeking human-relevant in vitro models that reduce reliance on animal testing.

1 investor

Vascugen develops an induced-pluripotent stem cell (iPSC)-derived vasculogenic cell therapy intended to form new blood vessels and restore microvascular circulation in oxygen-starved tissues. It targets diabetic and arterial disease patients at high risk of limb amputation, and handles development from R&D through cGMP manufacturing.

1 investor